Approval · Notice of Compliance 32932 · 2024
OKEDI: Notice of Compliance 32932
Issued March 21, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32932
- Date
- March 21, 2024
- Company
- Laboratorios Farmaceuticos Rovi, S.A.Madrid, Madrid, Spain
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
Medicinal ingredients
- RISPERIDONE 75 MG per SYR
- RISPERIDONE 100 MG per SYR